10-Q: MariMed Q2 Sees Revenue Dip, Net Loss Widens Amid IRS Lien

MariMed Inc. reported a slight revenue decrease and a wider net loss for H1 2025, alongside an IRS tax lien and OTCQX listing compliance concerns.

Summary

• MariMed Inc. reported a 2.0% decrease in total revenue for the three months ended June 30, 2025, to $39.611 million, and a 1.0% decrease for the six months ended June 30, 2025, to $77.566 million, compared to the prior year periods.
• Net loss improved for the three months ended June 30, 2025, to $(1.270) million from $(1.639) million, but widened significantly for the six months ended June 30, 2025, to $(6.690) million from $(2.931) million.
• Gross profit and gross margin declined for both the three and six-month periods, with gross margin falling to 40.2% for H1 2025 from 42.6% in H1 2024.
• Adjusted EBITDA increased for the three months ended June 30, 2025, to $4.912 million but decreased for the six months ended June 30, 2025, to $7.476 million.
• Wholesale product sales showed growth, increasing by 11.7% for H1 2025, while retail sales declined by 6.0% in key markets for the same period.
• The company faces a $6 million IRS tax lien for 2023 alleged tax liability, which it is disputing through a Collection Due Process Hearing.
• MariMed received a non-compliance notification from OTC Markets Group regarding its minimum bid price requirement for OTCQX listing, risking delisting if compliance is not met by September 8, 2025.
• Bad debt expense increased substantially to $1.644 million for the six months ended June 30, 2025, primarily due to a $1.5 million reserve for amounts due from two credit card service providers.
• Cash and cash equivalents decreased to $6.138 million at June 30, 2025, from $7.282 million at December 31, 2024.

Sentiment

Score: 3

Explanation: While Q2 Adjusted EBITDA showed a slight improvement and wholesale sales grew, the overall H1 financial performance (widening net loss, declining revenue and gross profit, lower H1 Adjusted EBITDA) is concerning. The $6 million IRS tax lien introduces substantial financial uncertainty, and the OTCQX delisting risk could severely impact the company's financial stability and access to capital. The significant increase in bad debt expense is also a negative.

Positives

• Adjusted EBITDA for the three months ended June 30, 2025, increased to $4.912 million from $4.371 million in the prior year.
• Net loss for the three months ended June 30, 2025, improved to $(1.270) million from $(1.639) million in the prior year.
• Wholesale product sales increased by $1.263 million (8.0%) for Q2 2025 and $3.544 million (11.7%) for H1 2025.
• Successfully completed the acquisition of First State Compassion Center (FSC) in Delaware, effective March 1, 2025, consolidating operations.
• Completed the acquisition of Allgreens Dispensary, LLC in Illinois, expanding the company's adult-use dispensary footprint to five in the state.
• Reopened the MedLeaf dispensary in Maryland for adult-use retail sales on August 19, 2024, providing a second dispensary in the state.
• Recognized a tax benefit of $1.7 million from the effective settlement of an IRS audit for the tax period ended December 31, 2022.
• Entered into a Management Services Agreement with Standard Farms, LLC (a TILT Holdings subsidiary) to manage cultivation and processing in Pennsylvania, with plans to distribute MariMed's brands.

Negatives

• Total revenue decreased by $0.827 million (2.0%) for the three months ended June 30, 2025, and by $0.805 million (1.0%) for the six months ended June 30, 2025.
• Net loss for the six months ended June 30, 2025, widened significantly to $(6.690) million from $(2.931) million in the prior year.
• Gross profit decreased by $0.877 million (5.2%) for Q2 2025 and $2.211 million (6.6%) for H1 2025, with gross margin declining to 40.5% and 40.2% respectively.
• Adjusted EBITDA for the six months ended June 30, 2025, decreased to $7.476 million from $9.032 million in the prior year.
• Retail product sales decreased by $1.184 million (5.0%) for Q2 2025 and $2.751 million (6.0%) for H1 2025, primarily due to lower sales in certain dispensaries in Illinois, Massachusetts, and Maryland.
• Other revenue decreased significantly by $0.906 million (95.7%) for Q2 2025 and $1.598 million (78.8%) for H1 2025 due to the cessation of revenue recognition from FSC post-acquisition.
• Bad debt expense increased substantially to $1.644 million for H1 2025, including a $1.5 million reserve for amounts due from two credit card service providers.
• Cash and cash equivalents decreased to $6.138 million at June 30, 2025, from $7.282 million at December 31, 2024.
• Operating activities provided less cash in H1 2025 ($1.6 million) compared to H1 2024 ($6.4 million), and financing activities used cash in H1 2025 ($(2.1) million) compared to providing cash in H1 2024 ($3.0 million).
• The company received a non-compliance notification from OTC Markets Group regarding its minimum bid price requirement for OTCQX listing, with a deadline of September 8, 2025, to regain compliance.
• The IRS filed a lien for approximately $6 million for 2023 alleged tax liability, which could materially impact operations and financial position if the company does not prevail in its dispute.
• An outstanding accrued liability of $2.0 million exists for electrical work performed by a related party, with ongoing discussions to address this liability and payment terms.

Risks

• Failure to comply with OTCQX listing standards, specifically maintaining a minimum bid price of $0.10 per share, could lead to removal from OTCQX and downgrade to a lower-tier market, impairing financing ability, reducing stock visibility/liquidity, and limiting access to institutional investors.
• The company is subject to U.S. Internal Revenue Code Section 280E, which significantly limits the deductibility of business expenses for cannabis operations, resulting in higher effective tax rates and potentially causing federal taxable income to exceed actual profits.
• The IRS filed a lien for an approximate $6 million 2023 alleged tax liability, and an unfavorable outcome in the ongoing dispute could materially impact operations and financial position, with the lien itself potentially having an adverse impact.
• Valuation of acquired intangible assets is inherently subjective and relies on significant unobservable inputs, with actual results potentially differing from estimates.
• Loss contingencies and reserves for legal claims and business risks require management estimates, which may need adjustment and could impact financial results.
• Credit risk on accounts receivable exists as the company provides credit to clients, and actual collections could differ from expected amounts, requiring additional reserves.
• Inventory valuation is based on judgmental estimates for factors like shrinkage, aging, future demand, and net realizable value, meaning actual sales amounts could differ from estimated values.
• Financial statements rely on management's estimates and judgments for various accounting policies, and actual results could differ significantly.
• Changes in general economic and business conditions, pricing levels, political/social/economic conditions in operating jurisdictions, and regulatory changes could adversely affect results.
• Increased competition, including from business partners, poses a risk to market share and profitability.
• Enforcement of U.S. federal cannabis-related laws and changes in such laws could materially impact operations.
• The remaining $5.9 million from the CREM Loan is held in escrow for the Hagerstown, Maryland cultivation facility expansion; delays or cost overruns could impact this project.
• Ongoing discussions to address a $2.0 million accrued liability for electrical work performed by a related party could result in unfavorable payment terms or disputes.

Future Outlook

The company expects its current cash and future funding opportunities to be sufficient to meet anticipated cash needs for working capital and capital expenditures for at least the next twelve months. Its strategic growth plan prioritizes increasing product brand revenue through enhanced cultivation, new product development, broader distribution, and market expansion. The plan also aims to increase retail store revenue by improving customer experience and expanding its dispensary footprint. The company is actively disputing a $6 million IRS tax lien and intends to pursue Tax Court litigation if necessary. Additionally, it anticipates Standard Farms will produce and distribute MariMed's brands in Pennsylvania upon regulatory approval. The company cannot predict the timing or occurrence of cannabis rescheduling or federal legislation affecting Section 280E.

Management Comments

• We continue to focus on executing our strategic growth plan, with priority on activities that include increasing our product brand revenue and increasing retail store revenue.
• Based on our current expectations, we believe our current cash and future funding opportunities will be sufficient to meet our anticipated cash needs for working capital and capital expenditures for at least the next twelve months.
• Our management believes that Adjusted EBITDA is a useful measure to assess our performance and liquidity, as it provides meaningful operating results by excluding the effects of expenses that are not reflective of our operating business performance.
• Inflation has impacted us through increased costs of ingredients, nutrients and packaging.
• We recently negotiated with certain of our suppliers to reduce our costs for future purchases of ingredients, nutrients and packaging, all of which have increased significantly as a result of current economic conditions.
• Our financial condition and results of its operations are not materially impacted by seasonal sales.

Industry Context

The U.S. cannabis industry continues to operate under federal illegality, subjecting companies like MariMed to IRC Section 280E, which significantly limits deductible business expenses and results in higher effective tax rates. MariMed's strategy of expanding its multi-state operator (MSO) footprint through acquisitions (FSC, Allgreens, MedLeaf) and licensing agreements (Standard Farms in Pennsylvania) aligns with broader industry trends to gain market share and diversify geographic presence in a fragmented regulatory landscape. The decline in retail sales in some markets could indicate increased competition or market saturation, while growth in wholesale suggests strength in brand distribution. Ongoing discussions about cannabis rescheduling or federal legislation affecting Section 280E remain critical industry-wide developments that could significantly alter the financial landscape for cannabis companies.

Corporate Governance

Legal Proceedings

• The IRS filed a lien against the company in June 2025 for an approximate $6 million 2023 alleged tax liability, which the company is disputing through a Collection Due Process (CDP) Hearing.
• There has been no material change to the status of previously reported legal proceedings, including the bankruptcy claim against GenCanna Global Inc., where MMH's general unsecured claim was reduced to $15.5 million and a liquidation distribution of $116,250 was received in Q3 2024.

Related Party Transactions

• Lease of corporate offices from an entity in which the CEO has an investment interest, with expenses of $68,000 for Q2 2025 and $145,000 for H1 2025.
• Purchases of nutrients, lab equipment, cultivation supplies, furniture, and tools from an entity owned by the COO's family, totaling $1.6 million for Q2 2025 and $2.9 million for H1 2025.
• Royalties paid on the Bettys Eddies product line to an entity owned by the COO and CCO, amounting to $156,000 for Q2 2025 and $319,000 for H1 2025.
• Distributions from a majority-owned subsidiary to the CEO (minority equity interest) of $1,300 for Q2 2025 and $3,000 for H1 2025.
• Distributions from Mari Holdings Metropolis, LLC to the CEO ($2,000 for Q2 2025, $5,000 for H1 2025) and COO ($6,000 for Q2 2025, $15,000 for H1 2025) who purchased membership units on June 10, 2024.
• Outstanding accounts payable balance of approximately $240,000 at June 30, 2025, primarily for fixed assets purchased from a CEO-controlled third-party company.
• Assumed accounts payable of $35,000 from FSC to a CEO-controlled company and $21,000 from FSC to a second CEO-controlled company.
• Mortgages with Bank of New England and DSB were personally guaranteed by the CEO at June 30, 2025.
• An accrued liability of $2.0 million for electrical work performed at New Bedford and Middleborough properties by an electrical contractor owned/controlled by the family of a non-officer/director stockholder.

Stakeholder Impact

• Shareholders face potential negative impacts from declining revenue and profitability trends, widening net loss, the $6 million IRS tax lien, and the risk of OTCQX delisting, which could reduce liquidity, visibility, and access to capital.
• Employees have seen increased headcount due to acquisitions, supporting the company's expanded footprint.
• Customers may benefit from the expansion of the company's dispensary footprint and product distribution, aiming to enhance product availability and experience.
• Suppliers are subject to negotiations by the company to reduce costs for ingredients, nutrients, and packaging.
• Creditors, particularly those holding mortgages and notes payable, are exposed to the company's financial performance and the potential impact of the IRS lien, with some obligations personally guaranteed by the CEO.
• Regulatory authorities are involved in ongoing disputes with the IRS, compliance with state cannabis regulations, and monitoring of OTC Markets Group listing standards.

Next Steps

• Regain compliance with OTCQX minimum bid price requirement by September 8, 2025, by maintaining a bid price of at least $0.10 per share for a minimum of 10 consecutive trading days.
• Dispute the IRS's $6 million alleged tax liability through a Collection Due Process (CDP) Hearing and pursue resolution, including potential reduction or collection alternatives.
• Initiate Tax Court litigation if necessary regarding the IRS tax lien.
• Continue executing the strategic growth plan, focusing on strengthening cultivation/processing, developing new products, broadening distribution, and expanding dispensary footprint.
• Complete the expansion of the Hagerstown, Maryland cultivation facility using escrowed CREM Loan proceeds.
• Obtain regulatory approval for Standard Farms to produce and distribute MariMed's brands in Pennsylvania.
• Address the $2.0 million accrued liability for electrical work at New Bedford and Middleborough properties through ongoing discussions with interested parties.
• Obtain final approval for the license transfer of Robust Missouri Process and Manufacturing, LLC.

Key Dates

Recommendation

The company faces significant headwinds. The widening net loss for the first half of the year, coupled with declining revenue and gross margins, indicates operational challenges. The $6 million IRS tax lien introduces substantial financial uncertainty and potential enforcement actions. Furthermore, the non-compliance with OTCQX listing standards and the risk of delisting could severely impair liquidity, access to capital, and investor confidence. While there are some positive strategic expansions, the immediate financial and regulatory risks outweigh these growth prospects, making the stock a high-risk investment with considerable downside potential.

Keywords

Cannabis, Multi-state operator, MSO, SEC filing, 10-Q, MariMed, Financial results, Q2 2025, Wholesale cannabis, Retail cannabis, Adjusted EBITDA, Net loss, Gross margin, IRS tax lien, OTCQX, Delaware, Illinois, Maryland, Massachusetts, Ohio, Pennsylvania, Cultivation, Dispensary, Edibles, Concentrates, Risk factors, Section 280E, Standard Farms, TILT Holdings